GLP-1 receptor agonists semaglutide and tirzepatide are associated with reduced risks of dementia, stroke, and mortality in adults with type 2 diabetes and obesity, new data show.

Binge eating disorder is strongly associated with weight gain and obesity, though not all individuals with obesity have BED.

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

Ozempic, a drug known for its physical health benefits, is now gaining recognition for its effectiveness in treating ...

The Canadian researcher has just received the Frontiers of Knowledge Award for his work on anti-obesity drugs. However, he ...

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

First Kellogg, then Kraft Heinz. Call it the anti-gestalt effect: the whole of a company can be worth less than its sum of ...

SHOPPING: Take charge of your health with help from Hims, the weight loss program that puts your specific needs front and ...

A new study suggests that drugs like Ozempic and Mounjaro may reduce dementia risk. Researchers at the University of Galway ...

A study reveals potentially fatal side effects of GLP-1 drugs, that people are using to lose weight. It’s well known that ...

A new study has found that older adults and women taking the weight-loss drug semaglutide may lose more muscle than others, ...